Rinvoq®

Active substance upadacitinib
Holder Abbvie
Status Running
Indication treatment of adults with severe Ankylosing Spondylitis who have no other suitable treatment option and are not eligible to participate in a clinical study.
Public documents Approbation
  Information for the patient
  Informed consent
Last update 03/06/2021

 

Last updated on 03/06/2021